The study on serum and urine of renal interstitial fibrosis rats induced by unilateral ureteral obstruction based on metabonomics and network analysis methods

Analytical and Bioanalytical Chemistry

Volumn 408, Issue 10, 2016, Pages 2607-2619

  Xiang, Zheng ^a,b   Sun, Hao ^b   Cai, Xiaojun ^b   Chen, Dahui ^b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Metabonomics; Network analysis; Renal interstitial fibrosis; UPLC Q TOF MS

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; BIOMOLECULES; BODY FLUIDS; ELECTRIC NETWORK ANALYSIS; FATTY ACIDS; GENES; METABOLITES; PHYSIOLOGY; UNSATURATED FATTY ACIDS;

BIOLOGICAL INFORMATION; GLYCEROPHOSPHOLIPIDS; METABONOMICS; MOLECULAR MECHANISM; RENAL INTERSTITIAL FIBROSIS; SPHINGOLIPID METABOLISM; UNILATERAL URETERAL OBSTRUCTIONS; UPLC Q-TOF MS;

METABOLISM;

ANIMAL; BLOOD; COMPLICATION; KIDNEY DISEASES; METABOLOMICS; RAT; SPRAGUE DAWLEY RAT; URETER OBSTRUCTION; URINE;

ANIMALS; KIDNEY DISEASES; METABOLOMICS; RATS; RATS, SPRAGUE-DAWLEY; URETERAL OBSTRUCTION;

EID: 84957976763     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-016-9368-4     Document Type: Article

References (57)

1. Zhang LX, Wang F, Wang L, Wang WK, Liu BC, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815-22.
2. Liu YH. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684-96.
3. Choi ME, Ding Y, Il Kim S. TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. Semin Nephrol. 2012;32(3):244-52.
4. Nishida M, Okumura Y, Sato H, Hamaoka K. Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy. Nephrol Dial Transpl. 2008;23(8):2520-4.
5. Xiao HB, Liu RH, Ling GH, Xiao L, Xia YC, Liu FY, et al. HSP47 regulates ECM accumulation in renal proximal tubular cells induced by TGF-beta 1 through ERK1/2 and JNK MAPK pathways. Am J Physiol-Renal. 2012;303(5):F757-65.
6. Farris AB, Colvin RB. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hy. 2012;21(3):289-300.
7. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181-9.
8. Boelaert J, t'Kindt R, Schepers E, Jorge L, Glorieux G, Neirynck N, et al. State-of-the-art non-targeted metabolomics in the study of chronic kidney disease. Metabolomics. 2014;10(3):425-42.
9. Zhao YY. Metabolomics in chronic kidney disease. Clin Chim Acta. 2013;422:59-69.
10. Kobayashi T, Yoshida T, Fujisawa T, Matsumura Y, Ozawa T, Yanai H, et al. A metabolomics-based approach for predicting stages of chronic kidney disease. Biochem Bioph Res Co. 2014;445(2):412-6.
11. van der Kloet FM, Tempels FWA, Ismail N, van der Heijden R, Kasper PT, Rojas-Cherto M, et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics. 2012;8(1):109-19.
12. Zhang HY, Jia JM, Cheng JG, Ye FQ, Li XK, Gao HC. H-1 NMR-based metabonomics study on serum of renal interstitial fibrosis rats induced by unilateral ureteral obstruction. Mol Biosyst. 2012;8(2):595-601.
13. Bauer-Mehren A. Integration of genomic information with biological networks using Cytoscape. Methods Mol Biol. 2013;1021:37-61.
14. Selimkhanov J, Taylor B, Yao J, Pilko A, Albeck J, Hoffmann A, et al. Systems biology. Accurate information transmission through dynamic biochemical signaling networks. Science. 2014;346(6215):1370-3.
15. Biro JC. Seven fundamental, unsolved questions in molecular biology - cooperative storage and bi-directional transfer of biological information by nucleic acids and proteins: an alternative to "central dogma". Med Hypotheses. 2004;63(6):951-62.
16. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68.
17. Emmert-Streib F, Glazko GV. Network biology: a direct approach to study biological function. Wires Syst Biol Med. 2011;3(4):379-91.
18. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90.
19. Liang XJ, Li HY, Li S. A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study. Mol Biosyst. 2014;10(5):1014-22.
20. Dalcanton A, Corradi A, Stanziale R, Maruccio G, Migone L. Effects of 24-hour unilateral ureteral obstruction on glomerular hemodynamics in rat-kidney. Kidney Int. 1979;15(5):457-62.
21. Shengbin X, Weiming W, Nan C. Progression of renal tubulointerstitial fibrosis and expression of α-SMA, TGF-β1 and VDR in rat UUO models. J Shanghai Jiaotong University (Medical Science). 2010;30(7):752-7.
22. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0 - the Human Metabolome Database in 2013. Nucleic Acids Res. 2013;41(Database issue):D801-807.
23. Tautenhahn R, Cho K, Uritboonthai W, Zhu ZJ, Patti GJ, Siuzdak G. An accelerated workflow for untargeted metabolomics using the METLIN database. Nat Biotechnol. 2012;30(9):826-8.
24. Horai H, Arita M, Kanaya S, Nihei Y, Ikeda T, Suwa K, et al. MassBank: a public repository for sharing mass spectral data for life sciences. J Mass Spectrom. 2010;45(7):703-14.
25. Xia J, Sinelnikov IV, Han B, Wishart DS (2015) MetaboAnalyst 3.0 - making metabolomics more meaningful. Nucleic acids Res 43(W1):W251-W257
26. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431-2.
27. Bauer-Mehren A, Rautschka M, Sanz F, Furlong LI. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks. Bioinformatics. 2010;26(22):2924-6.
28. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu YF, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(D1):D1091-7.
29. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edition. Brit J Pharmacol. 2009;158:S1-S239.
30. Qin C, Zhang C, Zhu F, Xu F, Chen SY, Zhang P, et al. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res. 2014;42(D1):D1118-23.
31. Floras JS, Aylward PE, Victor RG, Mark AL, Abboud FM. Epinephrine facilitates neurogenic vasoconstriction in humans. J Clin Invest. 1988;81(4):1265-74.
32. Abrass CK. Lipid metabolism and renal disease. Obesity and the Kidney. 2006;151:106-21.
33. Lamaziere A, Wolf C, Quinn PJ. Perturbations of lipid metabolism indexed by lipidomic biomarkers. Metabolites. 2012;2(1):1-18.
34. Kovacs KR, Bajko Z, Szekeres CC, Csapo K, Olah L, Magyar MT, et al. Elevated LDL-C combined with hypertension worsens subclinical vascular impairment and cognitive function. J Am Soc Hypertens. 2014;8(8):550-60.
35. Jung S, Kim M, Ryu HJ, Chae JS, Lee SH, Lee JH. Age-related increase in LDL-cholesterol is associated with enhanced oxidative stress and disturbed sphingolipid metabolism. Metabolomics. 2015;11(1):40-9.
36. Colles SM, Chisolm GM. Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res. 2000;41(8):1188-98.
37. Holub BJ, Swidinsky P, Park E. Oral docosapentaenoic acid (22:5n-3) is differentially incorporated into phospholipid pools and differentially metabolized to eicosapentaenoic acid in tissues from young rats. Lipids. 2011;46(5):399-407.
38. Aukema HM, Yamaguchi T, Takahashi H, Celi B, Holub BJ. Abnormal lipid and fatty-acid compositions of kidneys from mice with polycystic kidney-disease. Lipids. 1992;27(6):429-35.
39. Phang M, Lincz LF, Garg ML. Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J Nutr. 2013;143(4):457-63.
40. Aslam R, Saeed SA, Ahmed S, Connor JD. Lipoproteins inhibit platelet aggregation and arachidonic acid metabolism in experimental hypercholesterolaemia. Clin Exp Pharmacol Physiol. 2008;35(5-6):656-62.
41. Katayama T, Hino M, Yoshiyama S, Nakamura A, Kohama K. Hyper-contraction by the arachidonic acid of vascular smooth muscle. J Pharmacol Sci. 2005;97:245p-p.
42. Rifai A, Sakai H, Yagame M. Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis. Kidney Int. 1993;43:S95-9.
43. Dittmann M, Hoffmann HH, Scull MA, Gilmore RH, Bell KL, Ciancanelli M, et al. A serpin shapes the extracellular environment to prevent influenza A virus maturation. Cell. 2015;160(4):631-43.
44. Shearer GC, Carrero JJ, Heimburger O, Barany P, Stenvinkel P. Plasma fatty acids in chronic kidney disease: nervonic acid predicts mortality. J Renal Nutr. 2012;22(2):277-83.
45. Boyle J. Biology must develop its own big-data systems. Nature. 2013;499(7456):7.
46. Werner E. Life: an introduction to complex systems biology. Nature. 2007;446(7135):493-4.
47. Alroy I, Yarden Y. Signal transduction by growth factors: Information transfer and processing by biological networks. Nato Adv Sci I a-Lif. 1999;309:142-66.
48. Shaitan KV. Conformational dynamics and new approaches to the physical-mechanisms of elementary acts of mass-transfer, energy transformation, and information-transmission in biological macromolecular structures. Mol Biol. 1994;28(3):444-9.
49. Grossman A. Information-transfer in biological-systems - targeting of proteins to specific organelles or to the extracellular environment (secretion). Comp Biochem Phys B. 1988;91(3):389-424.
50. Zhou X, Kao MC, Wong WH. Transitive functional annotation by shortest-path analysis of gene expression data. Proc Natl Acad Sci U S A. 2002;99(20):12783-8.
51. Lan HY, Chung ACK. TGF-beta/Smad signaling in kidney disease. Semin Nephrol. 2012;32(3):236-43.
52. Provost P, Samuelsson B, Radmark O. Interaction of 5-lipoxygenase with cellular proteins. Proc Natl Acad Sci U S A. 1999;96(5):1881-5.
53. Hill LM, Gavala ML, Lenertz LY, Bertics PJ. Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol. 2010;185(5):3028-34.
54. Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, et al. P2X(7) receptor-Pannexin1 complex, pharmacology and signaling. (vol 295, pg C752. Am J Physiol-Cell Ph. 2008;296(3):C639-9.
55. Fu Y, Katsuya T, Matsuo A, Yamamoto K, Akasaka H, Takami Y, et al. Relationship of bradykinin B2 receptor gene polymorphism with essential hypertension and left ventricular hypertrophy. Hypertens Res. 2004;27(12):933-8.
56. Illi A, Kampman I, Anttila S, Roivas M, Mattila KM, Lehtimaki T, et al. Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharm. 2003;13(3):147-51.
57. Deschaepdryver A, Kirshner N (1961) Metabolism of adrenaline after blockade of monoamine oxidase and catechol-O-methyltransferase. Science 133 (345):586-&